Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Daratumumab Or Darzalex Market Size Shifted, And What Is the Outlook Through 2034?
In recent times, the market size for daratumumab, also known as darzalex, has seen rapid expansion. The market is projected to rise from its 2024 value of $5,093.04 million to $5,618.30 million in 2025, representing a compound annual growth rate (CAGR) of 10.3%. Factors contributing to this growth during the historical period include the implementation of various research channels, enhanced biomanufacturing operations feasibility, the increased usage of monoclonal antibodies, a rise in the number of strategic initiatives, and increased production of mAbs.
How Much Will the Daratumumab Or Darzalex Market Be Worth in 2029?
The market for daratumumab, also known as darzalex, is anticipated to expand significantly in the incoming years, projecting to reach $8,189.36 million by 2029 with a compound annual growth rate (CAGR) of 10.0%. This growth is attributed to a multitude of factors, including a surging occurrence of blood cancer, growing patient awareness, enhancement in clinical evidence, increasing demand for biologic medications, and the rise in chronic disease cases. Further, the forecast period is expected to witness key trends, including technological progression, the launch of novel products, availability of new services and/or products, strategic partnerships, consolidations, novel radiation technology advancements, and collaboration initiatives.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp
Which is the Largest Company in the Daratumumab Or Darzalex Market?
Major companies operating in the daratumumab or darzalex market include Genmab A/S, Janssen Biotech Inc.
What Are the Main Market Drivers in the Daratumumab Or Darzalex Industry?
The escalating occurrences of bone marrow cancer are anticipated to fuel the daratumumab or darzalex market’s expansion. Bone marrow cancer includes diseases like multiple myeloma and leukemia, which originate in the bone marrow, where abnormal blood cell production impacts the normal functioning of the body. The upsurge in cases of bone marrow cancers is credited to an aging demographic, enhanced detection techniques, and factors like environmental effects, lifestyle decisions, and genetic inclinations. Daratumumab (Darzalex) plays a significant role in treating multiple myeloma, a form of bone marrow cancer, by identifying and eliminating unusual plasma cells in the bone marrow. For example, the American Cancer Society, a non-profit organization devoted to cancer eradication, predicted in January 2024, that there would be 89,190 lymphoma cases, up from 89,010 in 2022. In addition, myeloma cases would rise to 35,780 from 34,470 in 2022. Therefore, the escalating prevalence of bone marrow cancer is stimulating the daratumumab or darzalex market expansion. The surge in the acceptance of biologics and targeted treatments is likely to stimulate the daratumumab or darzalex market’s growth. Targeted treatments imply a kind of medical intervention that uses drugs or other substances to precisely pinpoint and attack particular molecules involved in cancer or other diseases’ growth and survival. The use of biologics and targeted treatments is on the rise owing to the increasing prevalence of chronic diseases and advancements in precision medicine, which facilitates more personalized, efficient treatments. Daratumumab is utilized in targeted treatments due to its specific effect on CD38, a protein largely expressed on the surface of malignant plasma cells in multiple myeloma. For instance, according to the Advanced Therapy Treatment Centers (ATTC), a UK-based network helping introduce new advanced therapy medicinal products (ATMPs) to patients, annual investments in advanced therapies surged by 31% in 2022. Currently, the UK accounts for 14% of all global commercial ATMP clinical trials. Consequently, the surge in acceptance of biologics and targeted treatments is stimulating the growth of the daratumumab or darzalex market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp
How Is the Daratumumab Or Darzalex Market Segments Structured?
The daratumumab or darzalexmarket covered in this report is segmented –
1) By Drug Type: 100Mg Injection; 400Mg Injection
2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications
What Strategic Trends Are Transforming the Daratumumab Or Darzalex Market?
The primary trend in the daratumumab or darzalex market is a shift towards early intervention strategies in oncology treatment, particularly the use of combination therapies in the treatment of multiple myeloma and other forms of cancer. Combination therapies, treatments that utilize two or more medicinal agents with different action mechanisms, are being leveraged to enhance effectiveness, mitigate resistance, and potentially lower adverse effects relative to monotherapy, ultimately seeking to boost patient outcomes. For example, in July 2024, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), by Johnson & Johnson, a U.S. pharmaceutical company, received U.S. FDA endorsement. This approved combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) is prescribed for both induction and consolidation therapy in patients newly diagnosed with multiple myeloma (NDMM) who are suitable candidates for autologous stem cell transplant (ASCT). Thanks to this approval, a quadruplet therapy option is available at the initial diagnosis stage, promising improved patient outcomes.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report
Which Global Regions Offer the Highest Growth in the Daratumumab Or Darzalex Market?
North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19896
This Report Delivers Insight On:
1. How big is the daratumumab or darzalex market, and how is it changing globally?
2. Who are the major companies in the daratumumab or darzalex market, and how are they performing?
3. What are the key opportunities and risks in the daratumumab or darzalex market right now?
4. Which products or customer segments are growing the most in the daratumumab or darzalex market?
5. What factors are helping or slowing down the growth of the daratumumab or darzalex market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model